131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

Autor: Pat Doyle, Yu Tse Tsan, Pau-Chung Chen, Jung-Der Wang, Chien Mu Lin, Chang Hsing Lee
Rok vydání: 2013
Předmět:
Zdroj: European Journal of Nuclear Medicine and Molecular Imaging. 41:253-259
ISSN: 1619-7089
1619-7070
1997-2008
DOI: 10.1007/s00259-013-2541-5
Popis: To evaluate the association between (131)I therapy for thyroid cancer and risk of developing primary hyperparathyroidism.This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative (131)I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of (131)I therapy on the risk of developing primary hyperparathyroidism in the cohort.A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10(5) person-years. (131)I was used in the treatment of 6,153 patients (68.8%) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative (131)I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing (131)I dose (test for trend p = 0.51). No interaction was found between (131)I dose and age (p = 0.94) or (131)I dose and sex (p = 0.99).(131)I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.
Databáze: OpenAIRE
Externí odkaz: